RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring

December 18, 2017

Responsive image

MARLBOROUGH, Mass., Dec. 18, 2017 /PRNewswire/ — RXi Pharmaceuticals Corporation (NASDAQ: RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced positive results with its lead clinical compound RXI-109 in a Phase 2 clinical trial. RXI-109-1402 is…

Category: Precious Metals